Icagen and Pfizer Form Three Way Collaboration with Yale To Explore Chronic Pain Remedies

Chronic pain and epilepsy are debilitating disorders that affect millions of individuals in the US and throughout the world.

Read more »

A Unique Roadblock for Pfizer’s Osteoarthritis Drug

We’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform?

Read more »

Researchers, Healthcare Companies Seek to Give COPD Patients Some Breathing Room

Breathing is one of the most basic human functions, but for an estimated 12 million people in the United States, the simple act of drawing a breath can be difficult and even painful.

Read more »

No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business

Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.

Read more »

FDA Hopes to Keep Pharma Honest With “Bad Ad” Program

Last week, the FDA unveiled its “Bad Ad” program to encourage physicians to report questionable pharmaceutical sales pitches.

Read more »

Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results

Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.

Read more »

FDA to Collaborate with Pharma Companies on New TB Initiative

A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.

Read more »

Cancer Vaccines: Investing Opportunities Beyond Dendreon

Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.

Read more »

NicOx Reports Positive Data for Cholesterol Drug

NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.

Read more »

Ligand to Buy Struggling Metabasis

Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.

Read more »